glp 1 approval FDA just approved orforglipron (Foundayo), Eli Lilly's oral GLP-1 receptor agonist for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest FDA-Approved Dosages and Indications for
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12




























